Rznomics Inc.

Development of innovative treatments for cancer & intractable diseases through the RNA-based platform technology

General Information
Company Name
Rznomics Inc.
Founded Year
2017
Location (Offices)
Korea South +1
Founders / Decision Makers
Number of Employees
11
Industries
Biopharma, Biotechnology
Funding Stage
Series C
Social Media

Rznomics Inc. - Company Profile

Rznomics Inc. is a biopharmaceutical startup focused on developing innovative treatments for cancer and intractable diseases through its RNA-based platform technology called trans-splicing ribozyme. Established in 2017, Rznomics has gained recognition from bio-focused institutions and successfully raised a total of KRW 60.9 billion in funding, including a recent KRW 37.2 billion series C investment from Korea Development Bank, Partners Investment, IBK Capital, UTC 2019 BioVentureFund, QUAD Ventures, Shinhan Venture Investment, Aon, and SBI Investment Korea. In 2022 1H, Rznomics achieved a significant milestone with the approval of its RZ-001 IND submission for the HCC treatment by the MFDS, and the clinical trial for RZ-001 is underway. The company also boasts a robust pipeline including treatments for glioblastoma multiforme, Alzheimer’s disease, genetic ocular disease (retinitis pigmentosa), and circular RNA technology. Additionally, Rznomics is actively engaging in partnerships with global companies to explore opportunities for co-research, co-development, and licensing. Rznomics' dedication to developing safe and effective biopharmaceuticals in oncology, degenerative disease, and genetic disease, coupled with its strategic partnerships and substantial funding, positions the company as a promising player in the biopharma and biotechnology industries.

Taxonomy: biopharmaceuticals, RNA-based platform technology, oncology, genetic disease, trans-splicing ribozyme, clinical trials, new drug development, gene therapy, Alzheimer's disease, global partnerships, TIPS program, innovation, research funding, tagging not forced

Funding Rounds & Investors of Rznomics Inc. (3)

View All
Funding Stage Amount No. Investors Investors Date
Series C KRW37.20B 8 08 Jun 2022
Series B KRW10.50B 2 Synergy IB Investment 16 Apr 2021
Series A KRW12.00B - 30 Oct 2019

Latest News of Rznomics Inc.

View All

No recent news or press coverage available for Rznomics Inc..

Similar Companies to Rznomics Inc.

View All
Locanabio, Inc. - Similar company to Rznomics Inc.
Locanabio, Inc. Creating RNA-targeting gene therapies to treat devastating diseases
RiboNova, Inc. - Similar company to Rznomics Inc.
RiboNova, Inc. Focused on Mitochondrial Disease & other serious rare diseases. R007 is our P2 ready asset, we also have tRNA discovery.
ReviR Therapeutics - Similar company to Rznomics Inc.
ReviR Therapeutics Improve human health by Revising drug discovery using RNA and AI technologies
Vacino Biotech - Similar company to Rznomics Inc.
Vacino Biotech We protect you from threaten of COVID-19 virus infection.